RxDoctor Payments Data

Frank Bishop, MD

Ophthalmology · Fresno, CANPI 1538134796

Payments from drug & device makers

$6,954in general payments, 2019–2025

Across 99 payments — averaging $70.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Rxsight Inc$5K
  • Alcon$1K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$341
  • Biotissue Holdings Inc.$322
  • Kala Pharmaceuticals, Inc.$67
  • Sun Pharmaceutical Industries Inc.$60
  • plus $191 from 7 others

What the payments were for

  • Consulting fees$4,70868%
  • Speaking & faculty fees$320%
  • Travel & lodging$5728%
  • Food & beverage$1,64224%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,954 in reported general payments places this provider in the 75th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$255,758
Medicare patients
407
Services billed
1,598

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast21$22,568
Prednisolone Acetate350$13,025
Bromfenac Sodium43$9,257
MieboPerfluorohexyloctane/Pf12$8,811
BesivanceBesifloxacin Hcl36$7,775
EysuvisLoteprednol Etabonate15$7,427
Timolol Maleate87$6,812
LumiganBimatoprost15$6,250
InveltysLoteprednol Etabonate18$5,445
Cyclosporine12$4,845
ProlensaBromfenac Sodium14$4,781
MoxifloxacinMoxifloxacin Hcl111$2,703
CombiganBrimonidine Tartrate/Timolol12$2,673
Latanoprost211$2,396
Ketorolac Tromethamine136$2,278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo$25$31,37933 claims
Kala Pharmaceuticals, Inc.Eysuvis, Inveltys$67$12,87233 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Prolensa$341$12,55650 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →